Business
Spectral announces license agreement with Bio-Rad Pasteur S.A.
TORONTO, Nov. 19 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI) today announced that it has entered ...
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\nTORONTO, Nov. 19 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI) today\nannounced that it has entered into a non-exclusive license and material supply\nagreement with Bio-Rad Pasteur S.A., a leader in the manufacturing and\ndistribution of a broad range of products for the life science research and\nclinical diagnostics markets. Under the terms of the agreement, Spectral will\nprovide Bio-Rad with its leading single chain Troponin I reagents.\n\n\n"We are very pleased to partner with a company of Bio-Rad's stature and\nmarket reach. Bio-Rad's readiness to partner with us is a testament to our\nability to generate and commercialize products of high quality, value and\nutility," said Dr. Paul Walker, President and CEO of Spectral Diagnostics.\n"Most significantly, the consistent revenue stream over the term of the\nagreement will continue to provide our company with the non-dilutive capital\nnecessary to focus on Spectral's core business, the commercialization of our\nFDA cleared EAA(TM) Endotoxin Activity Assay for the detection of endotoxemia\nand the subsequent risk for Sepsis."\n\n\nSpectral's proprietary single chain Troponin I reagents are now in use by\nfive major international reagent supply and instrumentation companies.\n\n\nAbout Bio-Rad Pasteur S.A.\n\n\nBio-Rad Pasteur S.A. is a subsidiary of Bio-Rad Laboratories Inc (AMEX:\nBIO and BIOb), a company that has remained at the center of scientific\ndiscovery for more than 50 years manufacturing and distributing a broad range\nof products for the life science research and clinical diagnostics markets.\nThe company is renowned worldwide among hospitals, universities, major\nresearch institutions, as well as biotechnology and pharmaceutical companies\nfor its commitment to quality and customer service. Founded in 1952, Bio-Rad\nis headquartered in Hercules, California, and serves more than 85,000 research\nand industry customers worldwide through its global network of operations. The\ncompany employs over 6,300 people globally and had revenues of nearly\n$1.3 billion in 2006. For more information, visit www.bio-rad.com.\n\n\nAbout Spectral Diagnostics\n\n\nSpectral is a developer of innovative technologies for comprehensive\ndisease management. Spectral technologies provide accurate and timely\ninformation to clinicians enabling the early initiation ...